Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPJOHN INVESTING $50 MIL. FOR START-UP OF JAPANESE R&D

Executive Summary

UPJOHN INVESTING $50 MIL. FOR START-UP OF JAPANESE R&D to be called Upjohn Pharmaceuticals Ltd., the firm announced in a March 5 release. The new subsidiary will develop Upjohn discovered compounds for marketing by Japan Upjohn, the twenty-five year old 55-45 pharmaceutical marketing joint venture between Upjohn and Sumitomo. Upjohn Vice Chairman Theodore Cooper, MD/PhD, said that Upjohn established the new Japanese R&D arm "because we see in Japan a special opportunity to expand our scientific resource base and to broaden our drug-discovery and development efforts." Upjohn said that the new subsidiary will become the firm's largest research facility outside of Kalamazoo, Mich. Udo Axen, formerly director therapeutics products for Upjohn, has been named VP-Pharmaceutical R&D, Japan to head the new subsidiary of the U.S. corporation. Upjohn Pharmaceuticals "will conduct clinical and preclinical studies, direct drug registration activities and institute extensive pharmaceutical research and development activities," Upjohn explained. In addition, Upjohn said that the new subsidiary will also package drugs sold by Japan Upjohn.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel